Integrated Filing — IndAS



General information about company

Scrip Code 541400
NSE Symbol ZIMLAB
MSEI Symbol NOTLISTED
ISIN INE518E01015
Name of company ZIM Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 12-11-2025   10:00:00
End date and time of board meeting 12-11-2025   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 10-02-2025
Indicate Company website link for updated RPT policy of the Company www.zimlab.in
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 8,839.43 15,982.20
Other income 204.39 351.95
Total income 9,043.82 16,334.15
2 Expenses
(a) Cost of materials consumed 4,349.90 7,111.63
(b) Purchases of stock-in-trade 292.89 452.19
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (678.38) (598.52)
(d) Employee benefit expense 1,546.06 2,903.48
(e) Finance costs 315.94 646.29
(f) Depreciation, depletion and amortisation expense 482.83 961.81
(f) Other Expenses
1 Other Expenses 2,711.77 5,062.75
Total other expenses 2,711.77 5,062.75
Total expenses 9,021.01 16,539.63
3 Total profit before exceptional items and tax 22.81 (205.48)
4 Exceptional items 0.00 0.00
5 Total profit before tax 22.81 (205.48)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 11.21 (47.89)
9 Total tax expenses 11.21 (47.89)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 11.60 (157.59)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 11.60 (157.59)
17 Other comprehensive income net of taxes (13.46) (26.92)
18 Total Comprehensive Income for the period (1.86) (184.51)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4,873.58 4,873.58
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.03 -0.32
Diluted earnings (loss) per share from continuing operations 0.03 -0.32
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.03 -0.32
Diluted earnings (loss) per share from continuing and discontinued operations 0.03 -0.32
24 Debt equity ratio 0.48 0.48
25 Debt service coverage ratio 0.95 0.88
26 Interest service coverage ratio 1.07 0.68
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes 1 The above unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 November 2025 and 12 November 2025. The above results have been subjected to limited review by Statutory Auditor of the Company 2 These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard Ind AS notified under the Companies Indian accounting Standards Rules 2015 as amended as prescribed under Section 133 of the Companies Act 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India SEBI 3 The standalone financial results of the Company for the quarter and half year ended 30 September 2024 and year ended 31 March 2025 were reviewed audited by another auditor who expressed an unmodified conclusion opinion on those results on 09 November 2024 and 20 May 2025 respectively 4 During the quarter the Company has entered into an agreement for sale for transfer of one of its unused MIDC leasehold land along with building and certain assets thereon The transaction is expected to be completed before the financial year ending 31 March 2026 subject to fulfillment of conditions outlined in the agreement 5 Subsequent to the quarter end the Company has purchased a MIDC leasehold land adjacent to its existing plant 6 The Company is principally engaged in a single business segment which is pharmaceuticals There is no separate reportable segment as per Ind AS 108 Operating Segments



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 15,122.94
Capital work-in-progress 4,599.55
Investment property 0.00
Goodwill 0.00
Other intangible assets 419.51
Intangible assets under development 2,523.52
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 1,636.34
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 78.67
Total non-current financial assets 1,715.01
Deferred tax assets (net) 0.00
Other non-current assets 892.97
Total non-current assets 25,273.50
2 Current assets
Inventories 9,558.65
Current financial asset
Current investments 0.00
Trade receivables, current 8,930.70
Cash and cash equivalents 17.70
Bank balance other than cash and cash equivalents 63.47
Loans, current 0.00
Other current financial assets 38.18
Total current financial assets 9,050.05
Current tax assets (net) 0.00
Other current assets 2,027.45
Total current assets 20,636.15
3 Non-current assets classified as held for sale 293.02
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 46,202.67
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,873.58
Other equity 19,458.44
Total equity attributable to owners of parent 24,332.02
Non controlling interest
Total equity 24,332.02
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 4,672.39
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 146.84
Total non-current financial liabilities 4,819.23
Provisions, non-current 0.00
Deferred tax liabilities (net) 1,071.15
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 5,890.38
Current liabilities
Current financial liabilities
Borrowings, current 7,058.06
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 402.30
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 6,025.46
Total Trade payable 6,427.76
Other current financial liabilities 1,259.67
Total current financial liabilities 14,745.49
Other current liabilities 1,099.72
Provisions, current 53.11
Current tax liabilities (Net) 81.95
Deferred government grants, Current 0.00
Total current liabilities 15,980.27
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 21,870.65
Total equity and liabilites 46,202.67
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Measurements of defined employee benefit plans -1899000 -3798000
Total Amount of items that will not be reclassified to profit and loss (18.99) (37.98)
2 Income tax relating to items that will not be reclassified to profit or loss (5.53) (11.06)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (13.46) (26.92)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (205.48)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 646.29
Adjustments for decrease (increase) in inventories (911.65)
Adjustments for decrease (increase) in trade receivables, current 334.34
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 3.92
Adjustments for other financial assets, non-current 212.94
Adjustments for other financial assets, current 1,511.56
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (774.57)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 604.87
Adjustments for depreciation and amortisation expense 961.81
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 25.21
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (173.31)
Adjustments for dividend income 0.00
Adjustments for interest income 12.37
Adjustments for share-based payments 16.70
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (23.81)
Other adjustments for non-cash items 51.52
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 2,473.45
Net cash flows from (used in) operations 2,267.97
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 243.86
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,024.11
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 291.75
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 28.48
Purchase of property, plant and equipment 1,438.74
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.75
Interest received 0.59
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (1,700.67)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,690.04
Repayments of borrowings 1,199.44
Payments of lease liabilities 186.97
Dividends paid 0.00
Interest paid 653.24
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 7.76
Net cash flows from (used in) financing activities (341.85)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (18.41)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (0.25)
Net increase (decrease) in cash and cash equivalents (18.66)
Cash and cash equivalents cash flow statement at beginning of period 36.36
Cash and cash equivalents cash flow statement at end of period 17.70





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 ZIM Laboratories Limited Anwar Daud Managing Director and shareholder with significant influence Remuneration NA 73.37 6.34 8.28 Textual Information(1)
2 ZIM Laboratories Limited Anwar Daud Managing Director and shareholder with significant influence Any other transaction Rent paid to Dr. Anwar Daud Approved 14.62 6.40 6.58
3 ZIM Laboratories Limited Zulfiquar Kamal Director (Finance) Remuneration NA 45.94 3.47 5.05 Textual Information(2)
4 ZIM Laboratories FZE Zulfiquar Kamal Director (Finance) Remuneration NA 14.17 2.33 2.42 Textual Information(3)
5 ZIM Laboratories Limited Pachira Financial Services LLP Related Party of wholly owned Subsidiary ZIM Health Technologies Limited Any other transaction Professional Fees paid to Pachira Financial Services LLP Approved 30.00 5.40 3.75
6 ZIM Laboratories Limited ZIM Laboratories FZE Wholly owned subsidiary Sale of goods or services Approved 792.96 196.11 4.29
7 ZIM Laboratories Limited ZIM Health Technologies Limited Wholly owned subsidiary Any other transaction Professional Fees paid to ZIM Health Technologies Limited Approved 72.00 303.58 304.50
8 ZIM Laboratories Limited ZIM Health Technologies Limited Wholly owned subsidiary Any other transaction Deemed Investment NA 136.69 96.00 136.69 Textual Information(4)
9 ZIM Laboratories Limited SIA ZIM Laboratories Limited Wholly owned subsidiary Investment Approved 291.75 347.71 639.46
10 ZIM Laboratories FZE ZIM Scientific Office LLC Wholly owned subsidiary of ZIM Laboratories Limited FZE Advance NA (21.03) 21.03 0.00 Advance 0.00 NA Unsecured Businees Purpose
11 ZIM Laboratories Limited Chandrashekhar Mainde Executive Director and Chief Executive Officer Wholly owned subsidiary Any other transaction Rent Approved 12.00 2.16 2.16
Total value of transaction during the reporting period 1,462.47



Text Block

Textual Information(1) As per approval of Board of Directors or Shareholder as necessary
Textual Information(2) As per approval of Board of Directors or Shareholder as necessary
Textual Information(3) As per approval of Board of Directors or Shareholder as necessary
Textual Information(4) As per approval of Board of Directors or Shareholder as necessary